본문 바로가기
KERD
논문KCI 등재

Comparing the Benefits and Drawbacks of Stem Cell Therapy Based on the Cell Origin or Manipulation Process: Addressing Immunogenicity

박정규|Chang Sung-Ho
대한면역학회 (The Korean Association of Immunologists)|2023.12|Immune Network|제23권 제6호|pp. 1-16|DOI 10.4110/in.2023.23.e44

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Opportunity costCRISPR/Cas9ImmunogenicityHLA-matched/mismatched allogeneic cell therapyB2MKOUniversal cell therapy

초록

Mesenchymal stem cells (MSCs) are effective in treating autoimmune diseases and managing various conditions, such as engraftment of allogeneic islets. Additionally, autologous and HLA-matched allogeneic MSCs can aid in the engraftment of human allogeneic kidneys with or without low doses of tacrolimus, respectively. However, HLA alloantigens are problematic because cell therapy uses more HLA-mismatched allogeneic cells than autologous for convenience and standardization. In particular, HLA-mismatched MSCs showed increased Ag-specific T/B cells and reduced viability faster than HLA-matched MSCs. In CRISPR/Cas9-based cell therapy, Cas9 induce T cell activation in the recipient's immune system. Interestingly, despite their immunogenicity being limited to the cells with foreign Ags, the accumulation of HLA alloantigen-sensitized T/B cells may lead to allograft rejection, suggesting that alloantigens may have a greater scope of adverse effects than foreign Ags. To avoid alloantigen recognition, the β2-microglobulin knockout (B2MKO) system, eliminating class-I MHC, was able to avoid rejection by alloreactive CD8 T cells compared to controls. Moreover, universal donor cells in which both B2M and Class II MHC transactivator (CIITA) were knocked out was more effective in avoiding immune rejection than single KO. However, B2MKO and CIITA KO system remain to be controlled and validated for adverse effects such as the development of tumorigenicity due to deficient Ag recognition by CD8 T and CD4 T cells, respectively. Overall, better HLA-matching or depletion of HLA alloantigens prior to cell therapy can reduce repetitive transplantation through the long-term survival of allogeneic cell therapy, which may be especially important for patients seeking allogeneic transplantation.

Abstract

Mesenchymal stem cells (MSCs) are effective in treating autoimmune diseases and managing various conditions, such as engraftment of allogeneic islets. Additionally, autologous and HLA-matched allogeneic MSCs can aid in the engraftment of human allogeneic kidneys with or without low doses of tacrolimus, respectively. However, HLA alloantigens are problematic because cell therapy uses more HLA-mismatched allogeneic cells than autologous for convenience and standardization. In particular, HLA-mismatched MSCs showed increased Ag-specific T/B cells and reduced viability faster than HLA-matched MSCs. In CRISPR/Cas9-based cell therapy, Cas9 induce T cell activation in the recipient's immune system. Interestingly, despite their immunogenicity being limited to the cells with foreign Ags, the accumulation of HLA alloantigen-sensitized T/B cells may lead to allograft rejection, suggesting that alloantigens may have a greater scope of adverse effects than foreign Ags. To avoid alloantigen recognition, the β2-microglobulin knockout (B2MKO) system, eliminating class-I MHC, was able to avoid rejection by alloreactive CD8 T cells compared to controls. Moreover, universal donor cells in which both B2M and Class II MHC transactivator (CIITA) were knocked out was more effective in avoiding immune rejection than single KO. However, B2MKO and CIITA KO system remain to be controlled and validated for adverse effects such as the development of tumorigenicity due to deficient Ag recognition by CD8 T and CD4 T cells, respectively. Overall, better HLA-matching or depletion of HLA alloantigens prior to cell therapy can reduce repetitive transplantation through the long-term survival of allogeneic cell therapy, which may be especially important for patients seeking allogeneic transplantation.

참고문헌 (84)

  1. Saler M, "hASC and DFAT, multipotent stem cells for regenerative medicine : a comparison of their potential differentiation in vitro", Int J Mol Sci, 18, pp.2699~ (2017)
  2. Weiss AR, "Immunomodulation by mesenchymal stem cells(MSCs) : mechanisms of action of living, apoptotic, and dead MSCs", Front Immunol, 10, pp.1191~ (2019)
  3. Lynggaard CD, "Intraglandular off-the-shelf allogeneic mesenchymal stem cell treatment in patients with radiation-induced xerostomia : a safety study(MESRIX-II)", Stem Cells Transl Med, 11, pp.478~489 (2022)
  4. Chen CF, "Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells(ADSCs)ELIXCYTE® : a phase I", II, randomized, active-control, single-blind, multiple-center clinical trial, 2021, pp.12, 562~
  5. Meucci MC, "Cardiovascular effects of autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal in renal transplant recipients : an analysis of the randomized triton study", J Am Heart Assoc, 10, pp.e023300~ (2021)
  6. 모요셉, "Mesenchymal Stem Cells Attenuate Asthmatic Inflammation and Airway Remodeling by Modulating Macrophages", Monocytes in the IL-13-Overexpressing Mouse Model, 2022, pp.22(5), 1~24[DOI]
  7. Wang Y, "Understanding the immunological mechanisms of mesenchymal stem cells in allogeneic transplantation : From the aspect of major histocompatibility complex class i", Stem Cells Dev, 28, pp.1141~1150 (2019)
  8. 장성호, "Allogeneic ADSCs induce CD8 T cellmediated cytotoxicity and faster cell death after exposure to xenogeneic serum or proinflammatory cytokines", Experimental and Molecular Medicine, 51, pp.1~10 (2019), 생화학분자생물학회[DOI]
  9. Mukonoweshuro B, "Immunogenicity of undifferentiated and differentiated allogeneic mouse mesenchymal stem cells", J Tissue Eng, 5 (2014)
  10. Li C, "Application of induced pluripotent stem cell transplants : autologous or allogeneic?", Life Sci, 212, pp.145~149 (2018)
  11. Karahan GE, "Pre-existing alloreactive t and b cells and their possible relevance for pretransplant risk estimation in kidney transplant recipients", Front Med(Lausanne), 7, pp.340~ (2020)
  12. Lefaucheur C, "Antibody-mediated rejection of solid-organ allografts", N Engl J Med, 379, pp.2580~2582 (2018)
  13. Pulecio J, "Crispr", cas9-based engineering of the epigenome, 2017, pp.21, 431~447
  14. Gorecka J, "The potential and limitations of induced pluripotent stem cells to achieve wound healing", Stem Cell Res Ther, 10, pp.87~ (2019)
  15. Pei WD, "Epigenome editing by CRISPR", Cas9 in clinical settings : possibilities and challenges, 2020, pp.19, 215~228
  16. Scheiner ZS, "The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies", J Biol Chem, 289, pp.4571~4577 (2014)
  17. Morizane A, "MHC matching improves engraftment of iPSC-derived neurons in non-human primates", Nat Commun, 8, pp.385~ (2017)
  18. Embgenbroich M, "Current concepts of antigen cross-presentation", Front Immunol, 9, pp.1643~ (2018)
  19. Arzi B, "Therapeutic efficacy of fresh, allogeneic mesenchymal stem cells for severe refractory feline chronic gingivostomatitis", Stem Cells Transl Med, 6, pp.1710~1722 (2017)
  20. Arzi B, "Therapeutic efficacy of fresh, autologous mesenchymal stem cells for severe refractory gingivostomatitis in cats", Stem Cells Transl Med, 5, pp.75~86 (2016)
  21. Kamen DL, "Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE", Lupus Sci Med, 9, pp.e000704~ (2022)
  22. Jolly M, "Development and validation of the Lupus Impact Tracker : a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus", Arthritis Care Res(Hoboken), 66, pp.1542~1550 (2014)
  23. Hernigou P, "Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions decreases complications in patients with diabetes", Int Orthop, 39, pp.1639~1643 (2015)
  24. Oliveira RL, "In vivo immunogenic response to allogeneic mesenchymal stem cells and the role of preactivated mesenchymal stem cells cotransplanted with allogeneic islets", Stem Cells Int, 2017, pp.9824698~ (2017)
  25. Coemans M, "Analyses of the short-and long-term graft survival after kidney transplantation in Europe between 1986 and 2015", Kidney Int, 94, pp.964~973 (2018)
  26. Pan GH, "Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation : a prospective, non-randomized study", Oncotarget, 7, pp.12089~12101 (2016)
  27. Dreyer GJ, "Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation : the Neptune study, a phase I single-center study", Am J Transplant, 20, pp.2905~2915 (2020)
  28. Reinders ME, "Autologous bone marrow-derived mesenchymal stromal cell therapy with early tacrolimus withdrawal : the randomized prospective, single-center, open-label TRITON study", Am J Transplant, 21, pp.3055~3065 (2021)
  29. Večerić-Haler Ž, "Autologous mesenchymal stem cells for treatment of chronic active antibody-mediated kidney graft rejection : report of the phase i", ii clinical trial case series, 2022, pp.35, 10772~
  30. Kol A, "Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses", Stem Cell Res Ther, 6, pp.73~ (2015)
  31. Owens SD, "Allogeneic mesenchymal stem cell treatment induces specific alloantibodies in horses", Stem Cells Int, 2016, pp.5830103~ (2016)
  32. Kawamura T, "Cardiomyocytes derived from MHC-homozygous induced pluripotent stem cells exhibit reduced allogeneic immunogenicity in MHC-matched non-human primates", Stem Cell Reports, 6, pp.312~320 (2016)
  33. Nakagawa M, "A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells", Sci Rep, 4, pp.3594~ (2014)
  34. Chang SH, "Allogeneic ADSCs induce the production of alloreactive memory-CD8 T cells through HLA-ABC antigens", Cells, 9, pp.1246~ (2020)
  35. Joswig AJ, "Repeated intraarticular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model", Stem Cell Res Ther, 8, pp.42~ (2017)
  36. Wagner DL, "High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population", Nat Med, 25, pp.242~248 (2019)
  37. Arruda VR, "Strategies to modulate immune responses : a new frontier for gene therapy", Mol Ther, 17, pp.1492~1503 (2009)
  38. Deuse T, "De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans", Nat Biotechnol, 37, pp.1137~1144 (2019)
  39. He Y, "Heteroplasmic mitochondrial DNA mutations in normal and tumour cells", Nature, 464, pp.610~614 (2010)
  40. Yakes FM, "Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress", Proc Natl Acad Sci U S A, 94, pp.514~519 (1997)
  41. Badr Eslam R, "Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension", Cytotherapy, 19, pp.668~679 (2017)
  42. Hare JM, "Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy : the POSEIDON randomized trial", JAMA, 308, pp.2369~2379 (2012)
  43. Pigott JH, "Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses", Vet Immunol Immunopathol, 156, pp.99~106 (2013)
  44. Isakova IA, "Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo", PLoS One, 9, pp.e87238~ (2014)
  45. Colbath AC, "Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses : clinical and cytological comparisons suggest safety", Equine Vet J, 52, pp.144~151 (2020)
  46. Hwang JW, "A comparison of immune responses exerted following syngeneic, allogeneic, and xenogeneic transplantation of mesenchymal stem cells into the mouse brain", Int J Mol Sci, 21, pp.3052~ (2020)
  47. Rowland AL, "Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting", Stem Cells Transl Med, 10, pp.694~710 (2021)
  48. Hoornaert CJ, "Concise review : innate and adaptive immune recognition of allogeneic and xenogeneic cell transplants in the central nervous system", Stem Cells Transl Med, 6, pp.1434~1441 (2017)
  49. Merlot AM, "Unraveling the mysteries of serum albumin-more than just a serum protein", Front Physiol, 5, pp.299~ (2014)
  50. Tiruppathi C, "Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells", Proc Natl Acad Sci U S A, 93, pp.250~254 (1996)
  51. Haque N, "Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells", Int J Biol Sci, 11, pp.324~334 (2015)
  52. Ankrum JA, "Mesenchymal stem cells : immune evasive, not immune privileged", Nat Biotechnol, 32, pp.252~260 (2014)
  53. Stoddard-Bennett T, "Stem cell therapy for Parkinson’s disease : safety and modeling", Neural Regen Res, 15, pp.36~40 (2020)
  54. Verboket R, "Autologous cell-based therapy for treatment of large bone defects : from bench to bedside", Eur J Trauma Emerg Surg, 44, pp.649~665 (2018)
  55. Taylor CJ, "Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types", Cell Stem Cell, 11, pp.147~152 (2012)
  56. Lu Y, "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer", Nat Med, 26, pp.732~740 (2020)
  57. Charlesworth CT, "Identification of preexisting adaptive immunity to Cas9proteins in humans", Nat Med, 25, pp.249~254 (2019)
  58. Xian B, "The immune response of stem cells in subretinal transplantation", Stem Cell Res Ther, 6, pp.161~ (2015)
  59. Dudek AM, "Answered and unanswered questions in early-stage viral vector transduction biology and innate primary cell toxicity for ex-vivo gene editing", Front Immunol, 12, pp.660302~ (2021)
  60. Zha S, "Generation of mesenchymal stromal cells with low immunogenicity from human PBMC-derived beta2 microglobulin knockout induced pluripotent stem cells", Cell Transplant, 29 (2020)
  61. Morvan MG, "NK cells and cancer : you can teach innate cells new tricks", Nat Rev Cancer, 16, pp.7~19 (2016)
  62. 신민화, "NK Cell-Based Immunotherapies in Cancer", Immune Network, 20(2), pp.1~27 (2020), 대한면역학회[DOI]
  63. Gornalusse GG, "HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells", Nat Biotechnol, 35, pp.765~772 (2017)
  64. Wang C, "The immune-related role of beta-2-microglobulin in melanoma", Front Oncol, 12, pp.944722~ (2022)
  65. Zhao Y, "B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy", Immunology, 164, pp.507~523 (2021)
  66. Wagner DL, "Immunogenicity of CAR T cells in cancer therapy", Nat Rev Clin Oncol, 18, pp.379~393 (2021)
  67. Jensen MC, "Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20", CD19-specific chimeric antigen receptor redirected T cells in humans, 2010, pp.16, 1245~1256
  68. Berger C, "Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation", Blood, 107, pp.2294~2302 (2006)
  69. Zhou X, "Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation", Blood, 125, pp.4103~4113 (2015)
  70. Di Stasi A, "Inducible apoptosis as a safety switch for adoptive cell therapy", N Engl J Med, 365, pp.1673~1683 (2011)
  71. Wiebking V, "Metabolic engineering generates a transgene-free safety switch for cell therapy", Nat Biotechnol, 38, pp.1441~1450 (2020)
  72. Kagoya Y, "Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy", Cancer Immunol Res, 8, pp.926~936 (2020)
  73. Halm D, "Direct comparison of the immunogenicity of major histocompatibility complex-I and-II deficient mesenchymal stem cells in vivo", Biol Chem, 402, pp.693~702 (2021)
  74. Wang X, "Diminished expression of major histocompatibility complex facilitates the use of human induced pluripotent stem cells in monkey", Stem Cell Res Ther, 11, pp.334~ (2020)
  75. Mattapally S, "Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells : universal donor for cell therapy", J Am Heart Assoc, 7, pp.e010239~ (2018)
  76. Lee J, "Abrogation of HLA surface expression using CRISPR", Cas9 genome editing : a step toward universal T cell therapy, 2020, pp.10, 17753~
  77. Rawat S, "Dexamethasone priming enhances stemness and immunomodulatory property of tissue-specific human mesenchymal stem cells", BMC Dev Biol, 21, pp.16~ (2021)
  78. Kot M, "The importance of HLA assessment in"off-the-shelf"allogeneic mesenchymal stem cells based-therapies", Int J Mol Sci, 20, pp.5680~ (2019)
  79. Shah K, "Alloreactivity of allogeneic mesenchymal stem", stromal cells and other cellular therapies : a concise review, 2022, pp.2022, 9589600~
  80. Mo F, "Engineered off-the-shelf therapeutic T cells resist host immune rejection", Nat Biotechnol, 39, pp.56~63 (2021)
  81. Srinivasan A, "Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion", Cytotherapy, 24, pp.456~472 (2022)
  82. Juneja T, "Utilization of Treg cells in solid organ transplantation", Front Immunol, 13, pp.746889~ (2022)
  83. Proics E, "Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation", Gene Ther, 30, pp.309~322 (2023)
  84. Atif M, "Regulatory T cells in solid organ transplantation", Clin Transl Immunology, 9, pp.e01099~ (2020)

관련 논문AI추천

Generation of hypoimmunogenic universal iPS cells through HLA-type gene knockoutChoi SeonJu, Choi Yujin, Hong Chang Pyo, Jeon Doyeong, Ju Ji Hyeon, Jung Hyerin, Kim Juryun, Kim Siyoung, Nam Yoojun, Park Narae, Rim Yeri Alice, Sohn Yeowon생화학분자생물학회 · Experimental and Molecular Medicine2025 · 제57권 Usage of Human Mesenchymal Stem Cells in Cell-based Therapy: Advantages and Disadvantages김희정, 박정수한국발생생물학회 · 발생과 생식2017 · 제21권 제1호Highly efficient genome editing via CRISPR-Cas9 ribonucleoprotein (RNP) delivery in mesenchymal stem cellsA Reum Han, Eun-Ju Chang, Eun-Young Kim, Ha Rim Shin, Jiyeon Kweon, Sang Eun Lee, Seong Who Kim, Soo Been Lee, Yongsub Kim생화학분자생물학회 · BMB Reports2024 · 제57권 제1호Stem Cell Therapy for Type 1 Diabetes Mellitus유은경대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2012 · 제17권 제2호Recent technological updates and clinical applications of induced pluripotent stem cells이재철, 정승민, 주지현, Sebastian Diecke대한내과학회 · The Korean Journal of Internal Medicine2014 · 제29권 제5호Mesenchymal Stem Cell-derived Exosomes: Applications in Cell-free Therapy김진관, 허준석대한임상검사과학회 · 대한임상검사과학회지2018 · 제50권 제4호

이 간행물의 다른 논문 (5건)

Intranasal Immunization With Nanoparticles Containing an Orientia tsutsugamushi Protein Vaccine Candidate and a Polysorbitol Transporter Adjuvant Enhances Both Humoral and Cellular Immune Responses윤철희, Kim Narae, Kim Cheol Gyun, Kim Won Kyong, Pyung Young Jin, Park Da-Jeong, Lee Jeong-Cheol, Cho Chong-Su, Chu Hyukpp. 1-16Recombinant Human Bone Morphogenetic Protein-2 Priming of Mesenchymal Stem Cells Ameliorate Acute Lung Injury by Inducing Regulatory T Cells양세란, Hong Seok-Ho, Lee Young Jin, Lee Jooyeon, Jang Jimin, Cha Sang-Ryul, Lee Se Bi, Bae Han-Solpp. 1-21Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms이상일, 김민교, Park Jung Min, Cheon Yun-Hong, Lee Sung-Lim, Lee Young Jin, Lee Hanna, Jeong Ok-Yi, Park Hee Jin, Bok Eun-yeong, Suh Young Sun, Kim Hyun-Ok, Kim Suhee, Chun Sung Hakpp. 1-22Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine노지윤, 송준영, Hwang Soon Young, Lee Jungmin, Kim Woo Joo, Cheong Hee Jin, Yoon Jin Gu, Park Man-Seong, Nham Eliel, Kim Jineui, Park Heedo, Kim Jeonghun, Lee Sohyun, Choi Jaeuk, Kim Kyung Taekpp. 1-10IL-17 Imbalance Promotes the Pyroptosis in Immune-Mediated Liver Injury Through STAT3-IFI16 AxisWang Hong, Wang Yanan, Xu Wenfang, Jin Changzhong, Zhang Weiyang, Chen Jiangnan, Chen Xuefang, Gao Junli, Gao Junshunpp. 1-16
원문 보기